Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma (Nasdaq: BBIO) announced topline results from its Phase 1/2 ADventure study of BBP-631, an investigational gene therapy for congenital adrenal hyperplasia (CAH). The study showed increased endogenous cortisol production in all patients at higher doses, with a maximum change from baseline of 6.6 μg/dL. The therapy was well-tolerated with no treatment-related serious adverse events. Despite these advancements, BridgeBio decided the data do not warrant additional capital investment. The company is reducing its gene therapy budget by over $50M and seeking partnership opportunities for future development of BBP-631 or next-generation CAH gene therapies.
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, has announced the approval of equity grants for 123 new employees. The grants, approved on September 4, 2024, consist of restricted stock units totaling 359,926 shares of the Company's common stock. The vesting schedule begins with one-fourth of the shares vesting on August 16, 2025, followed by quarterly vesting of one-twelfth of the remaining shares, subject to continued employment. These awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as inducement material for new employees joining the Company.
BridgeBio Pharma (Nasdaq: BBIO) presented additional data from its Phase 3 ATTRibute-CM and open-label extension study of acoramidis in ATTR-CM at ESC 2024. Key findings include:
1. Participants switching from tafamidis and placebo to acoramidis showed a mean increase in serum TTR of 3.0mg/dL at Month 1 and 3.4mg/dL at Month 6 of the OLE.
2. Increased serum TTR at Day 28 correlated with reduced risk of all-cause mortality, cardiovascular mortality, and cardiovascular-related hospitalization.
3. Acoramidis demonstrated a 42% reduction in composite CVH and ACM events and a 50% reduction in cumulative CVH events at Month 30.
BridgeBio has submitted regulatory applications for acoramidis, with FDA PDUFA date set for November 29, 2024, and EMA decision expected in 2025.
BridgeBio Pharma (Nasdaq: BBIO) announced that additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM will be presented at two major conferences. At the ESC Congress 2024 in London (Aug 30 - Sep 2), Dr. Mathew S. Maurer will present a moderated poster on the increase in serum TTR levels observed with acoramidis treatment. At the HFSA Annual Scientific Meeting 2024 in Atlanta (Sep 27-30), Dr. Daniel P. Judge will give an oral presentation on how acoramidis improves clinical outcomes in ATTR-CM patients, based on a post hoc recurrent event analysis. These presentations aim to provide further insights into the efficacy of acoramidis in treating transthyretin amyloid cardiomyopathy.
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases, has announced its participation in three major investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Health Care Conference in New York, NY on September 4th at 10:00 am ET (Fireside Conversation)
2. Wells Fargo 19th Annual Healthcare Conference 2024 in Boston, MA on September 5th
3. Cantor Global Healthcare Conference in New York, NY on September 17th at 10:20 am ET (Presentation)
Investors can access live webcasts of BridgeBio's presentations on the company's website. Replay of the webcasts will be available for 90 days following each event.
BridgeBio Pharma (Nasdaq: BBIO) has initiated a scientific collaboration with the CarDS Lab at Yale School of Medicine to address the underdiagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). The TRACE-AI Network Study will deploy a scalable screening toolkit across diverse health system electronic health records (EHRs) to identify individuals with ATTR-CM earlier and quantify the potential prevalence of undiagnosed cases.
The CarDS Lab has developed novel deep learning tools applied to real-world data sets, including AI-electrocardiography, AI-point-of-care ultrasound, and AI-echocardiography, which may identify potentially missed ATTR-CM cases with high accuracy. This initiative aims to improve diagnosis across the U.S. and potentially enhance outcomes for patients in need.
BridgeBio Pharma (Nasdaq: BBIO) and its affiliate QED Therapeutics have launched MyAchonJourney, an online resource for families navigating achondroplasia. Developed in collaboration with skeletal dysplasia community leaders, the initiative aims to provide education and support for families affected by achondroplasia.
The initial phase of MyAchonJourney offers guidance on medical topics, psychosocial issues, and quality-of-life adaptations for children up to five years old. It covers pregnancy, birth, infancy, toddlerhood, and early childhood, with plans to expand resources for older children, teenagers, and young adults in future phases.
The platform was created with input from a task force of experts, including medical professionals and community advocates, to ensure comprehensive and reliable information for families navigating life with achondroplasia.
BridgeBio Pharma (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focusing on genetic diseases, has announced the approval of equity grants for 17 new employees. The grants, approved by the compensation committee on August 6, 2024, consist of restricted stock units totaling 71,859 shares of the company's common stock. The vesting schedule includes one-fourth of the shares vesting on August 16, 2025, followed by quarterly vesting of one-twelfth of the remaining shares, subject to continued employment. These grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as inducements for the new employees joining the company.
BridgeBio Pharma reported its Q2 2024 financial results, focusing on significant clinical trial progress and financial updates. Acoramidis demonstrated a 42% reduction in composite CVH and ACM events by Month 30, with improvements starting by Month 3. Infigratinib showed +2.50 cm/yr annualized height velocity at Month 18 in Cohort 5 of the PROPEL 2 study. The company exceeded its enrollment target for the Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9. Financially, BridgeBio ended the quarter with $587M in cash, driven by various financing activities. Revenue for the quarter was $2.2M, up from $1.6M in the same period last year, primarily due to collaborations with Bayer and Kyowa Kirin. Operating costs increased to $177.7M, leading to a net loss per share of $0.39, an improvement from $0.98 in Q2 2023.
BridgeBio Pharma (Nasdaq: BBIO) has appointed Thomas Trimarchi, Ph.D., as President and Chief Operating Officer (COO), effective immediately. In this newly created role, Dr. Trimarchi will drive operational excellence, strategic planning, and overall business success, reporting directly to CEO Neil Kumar, Ph.D. He will lead cross-functional activities to develop a centralized operation across the late-stage pipeline, focusing on efficiency, rigor, and scale.
Dr. Trimarchi, who joined BridgeBio in 2018, previously served as Chief Product Officer and is a board member of ML Bio Solutions, a BridgeBio affiliate. His prior experience includes roles at Regeneron Pharmaceuticals and Goldman Sachs. CEO Kumar praised Trimarchi's patient-first approach and data-driven decision-making, expressing excitement about the continued growth and impact on patients under his leadership.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
